Review
Biochemistry & Molecular Biology
Perla Chami, Youssef Diab, Danny N. Khalil, Hassan Azhari, William R. Jarnagin, Ghassan K. Abou-Alfa, James J. Harding, Joseph Hajj, Jennifer Ma, Maria El Homsi, Marsha Reyngold, Christopher Crane, Carla Hajj
Summary: The liver tumor immune microenvironment plays a crucial role in the development and progression of HCC. While immune checkpoint inhibitors have limited efficacy in HCC, it has been found that radiation therapy can overcome some of these limitations and reshape the liver immune microenvironment. Combining radiation therapy with immune checkpoint inhibitors effectively restores anti-tumor activity.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Yawen Dong, Jeffrey Sum Lung Wong, Ryohichi Sugimura, Ka-On Lam, Bryan Li, Gerry Gin Wai Kwok, Roland Leung, Joanne Wing Yan Chiu, Tan To Cheung, Thomas Yau
Summary: Hepatocellular carcinoma is a highly aggressive cancer with a poor prognosis. Immune checkpoint inhibitors targeting the PD-1/L1 pathway have shown promise in systemic treatment, but challenges remain in predicting treatment response and optimizing outcomes. Strategies involving combination therapy with other agents and exploring alternative pathways are being investigated to improve efficacy. Multiple biomarkers are being studied to predict response to immune checkpoint inhibitors in HCC.
Review
Gastroenterology & Hepatology
Byung Min Lee, Jinsil Seong
Summary: ICIs have shown clinical efficacy against most solid cancers, and recent success in combination therapy with targeted agents in hepatocellular carcinoma has accelerated the search for novel combination strategies. Additionally, radiotherapy can be combined with ICIs to modulate the tumor immune microenvironment.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Immunology
JianBin Wu, Yuanyuan Zhu, MingMin Luo, Lei Li
Summary: This study revealed the crucial role of pyroptosis in breast cancer, showing its association with tumor progression, prognosis, and immunotherapy response. Evaluating the PyroptosisScore of a single tumor can help understand the characteristics of tumor microenvironment infiltration and lead to the development of more effective immunotherapy strategies.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Materials Science, Multidisciplinary
Xin Li, Yu Zhen, Shanshan Li
Summary: This article reviews the significance of immune checkpoint blockade, photodynamic therapy, and nanotechnology in cancer treatment, highlighting the promising results of their combination in preclinical models and potential clinical applications.
MATERIALS & DESIGN
(2021)
Review
Immunology
Jiuhui Xu, Qianyu Shi, Boyang Wang, Tao Ji, Wei Guo, Tingting Ren, Xiaodong Tang
Summary: Chordoma is a rare malignant bone tumor with limited therapeutic options. Recent research has shown the importance of the tumor immune microenvironment in its development. This review summarizes previous studies on the immune microenvironment of Chordoma and proposes promising immunotherapy strategies.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Won Jin Jeon, Jin Hyun Moon, Bryan Pham, Bowon Joung, Laura Denham, Joel Brothers
Summary: Undifferentiated pleomorphic sarcoma (UPS) is a rare subtype of soft tissue sarcoma (STS) with a poor prognosis. Surgical resection is the only potentially curative treatment. The role of perioperative systemic therapy is still not clear. Managing UPS can be challenging due to high recurrence rates and metastatic potential, especially in cases where surgery is not feasible or patients have comorbidities and poor performance status (PS). Here, we report a case of UPS involving the chest wall in a patient with poor PS who achieved complete response (CR) after neoadjuvant chemotherapy and radiation following prior immune-checkpoint inhibitor (ICI) therapy.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Claudia Trojaniello, Jason J. Luke, Paolo A. Ascierto
Summary: Melanoma, the most fatal skin cancer, has seen a significant revolution in treatment since 2011 with targeted therapy and immunotherapy. Current research focuses on preventing resistance, increasing drug effectiveness, and exploring new treatment combinations and targets to benefit more patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Immunology
Changhee Park, Dong Young Jeong, Yeonu Choi, You Jin Oh, Jonghoon Kim, Jeongun Ryu, Kyunghyun Paeng, Se-Hoon Lee, Chan-Young Ock, Ho Yun Lee
Summary: Artificial intelligence-powered TIL analysis in H&E images and the analysis of quantitative radiomic features in CT images can objectively assess the enrichment of TILs in NSCLC patients. The prediction of TIL enrichment using these methods may be a reliable biomarker for ICI outcomes in NSCLC patients, helping in the clinical decision-making process.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Yaxiong Tang, Xu Hu, Kan Wu, Xiang Li
Summary: Penile cancer is a rare malignancy with limited treatment options and poor prognosis. Immune-based therapies, HPV vaccine, and adoptive T cell therapy have shown potential as treatment modalities.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Yasuyuki Tamai, Naoto Fujiwara, Takamitsu Tanaka, Shugo Mizuno, Hayato Nakagawa
Summary: Hepatocellular carcinoma is the fourth leading cause of cancer-related deaths worldwide. Immune checkpoint inhibitors have improved the therapeutic efficacy for advanced HCC, but their response rates are still unsatisfactory. Researchers are actively exploring combination therapies of ICIs with locoregional therapy to overcome this limitation.
Review
Oncology
Li Tao, Huiyun Zhang, Guangyu An, Haoning Lan, Yaoqi Xu, Yang Ge, Jiannan Yao
Summary: A systematic review and meta-analysis showed that in patients with metastatic renal cell carcinoma, receiving a combination therapy of ICIs and anti-VEGF can significantly improve overall survival, progression-free survival, and objective response rate, at the cost of increased risk of specific adverse events.
FRONTIERS IN ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Maria Rodriguez Pla, Diego Dualde Beltran, Eduardo Ferrer Albiach
Summary: A systematic review was conducted to evaluate the possible synergistic effects of immune checkpoints inhibitors (ICIs) and stereotactic radiation therapy in melanoma and NSCLC. The combined treatment of ICI-SBRT/SRS achieves high local control and non-negligible abscopal response in patients with extracerebral metastases, with its benefit in cerebral metastases being more controversial.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Jin Yang, Ran Zeng, Jianping Zhou, Lifeng Luo, Mengchen Lyu, Fang Liu, Xianwen Sun, Ling Zhou, Xiaofei Wang, Zhiyao Bao, Wei Chen, Daphne W. Dumoulin, Beili Gao, Yi Xiang
Summary: This study aimed to explore the efficacy, prognosis, and safety of patients with advanced lung cancer who received immune checkpoint inhibitor rechallenge. The findings suggest that rechallenge may be an attractive option for patients who discontinued treatment due to immune-related adverse events, but further research is needed for patients with disease progression.
TRANSLATIONAL LUNG CANCER RESEARCH
(2022)
Article
Oncology
Elvelyn R. Fernandez, Deborah Tamura, Sikandar G. Khan, Sophie Momen, Hiva Fassihi, Robert Sarkany, John J. Digiovanna, Kenneth H. Kraemer
Summary: In this retrospective study, XP patients with metastatic or unresectable cancers showed positive responses to ICI and the treatment was well tolerated. The types and frequencies of adverse events in XP patients were similar to those in the general population. However, some XP patients developed new skin cancers while being treated with ICI.
FRONTIERS IN ONCOLOGY
(2023)